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BACKGROUND: The purpose of the research question is to
develop an explicit priority setting methodology to support deci-
sion-making regarding Medicinal Products and Medical Devices
to be included in hospital pharmacy practice. The development of
a comprehensive prioritization system is the outcome essential for
an important benefit to the healthcare system. The aim of this
paper is to identify and analyze the processes and decision criteria
used internationally for priority setting in order to establish a
comprehensive set of strategic criteria for starting point for the
development of a Medicinal Products and Medical Devices priori-
tization framework.
METHODS: A systematic search of the literature was carried out
in December 2017, in the main biomedical electronic databases:
Medline/PubMed, Embase, Centre for Reviews and Dissemination
(CRD), and Cochrane. Eligibility criteria for inclusion were based
on set of predefined criteria. Systematic reviews and/or qualitative
studies (interviews, surveys, expert consensus, etc) that aimed to
identify prioritization criteria or develop general operational frame-
works for the selection of health priorities were included. Data of
the studies were analyzed and synthesized qualitatively.
RESULTS: A total of 17 documents complied with eligibility cri-
teria, 15 were published in scientific journals and 2 were identified
through web pages. The studies showed great heterogeneity. A
total of 56 potentially relevant priority setting criteria were identi-
fied, which could be grouped in 8 categories: 1) Need for inter-
vention; 2) Outcomes of intervention; 3) Type of benefit; 4)
Economic consequences; 5) Existing knowledge/quality of evi-
dence and uncertainties; 6) Implementation complexity/feasibility;
7) Priority, justice and equity; and 8) Context.
DISCUSSION: There are no standardized processes for priority
setting, despite the fact some general consensus and common
trends have been identified regarding criteria, models and strate-
gies, and key actors. This research provides a thorough analysis
of these approaches and offers recommendations for implement-
ing successful prioritization approaches.
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BACKGROUND: The number and the importance of economic
evaluation studies of ophthalmic drugs have been growing. This
study aims at reviewing economic evaluation studies of oph-
thalmic drugs and identifying the sources of effectiveness mea-
sures used.
METHODS: A systematic search, according to PRISMA orienta-
tions, was conducted in Medline and Embase from its inception until
June 2017. Only full studies were included, therefore cost-minimiza-
tion analyses were excluded. Therapeutic areas, interventions, type
of analysis and sources of effectiveness measures were identified. The
methodological-quality of the economic studies was evaluated
according to the British Medical Journal (BMJ) checklist.
RESULTS: Eighty-six studies were included. Forty-three (50%)
were cost-utility analysis, 28 (33%) cost-effectiveness analysis and 15
(17%) simultaneously cost-effectiveness/cost-utility analysis. The
main therapeutic areas were age-related macular degeneration
(n=35; 40.7%), glaucoma/ocular hypertension (n=19; 22.1%) and
conjunctivitis (n=7; 8.1%). Biologic agents (n=57; 39.3%), vertepor-
fin (n=11; 7.6%), and bimatoprost (n=11; 7.6%) were the most eval-
uated drugs. Of the 43 cost-utility studies, 18 (41.9%) retrieved
effectiveness measures exclusively from observational studies, 9
(20.9%) exclusively from experimental studies, and four (9.3%) from
both. Of the 28 cost-effectiveness studies, 15 (53.6%) retrieved effec-
tiveness measures exclusively from experimental studies, four
(14.3%) exclusively from observational studies, and one (4.2%) from
both. Of the 15 cost-effectiveness/cost-utility studies, nine (60%)
retrieved effectiveness data from both experimental and observa-
tional studies, and one (6.7%) exclusively from experimental studies.
All studies demonstrated methodological-quality limitations.
DISCUSSION: Cost-utility analysis was the most used technique
to assess the pharmacoeconomic value of ophthalmic drugs, fre-
quently using observational data sources. However, a great
methodological heterogeneity was found among studies.
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BACKGROUND: Warfarin is a widely prescribed oral anticoagu-
lant especially in populations with low socioeconomic status. Dif-
ferent populations demonstrate inconsistencies in the
pharmacogenetic determinants of warfarin dose requirements.
Moreover, there is a paucity of the pharmacogenetics studies con-
ducted on the genetically diverse African populations. Hence,
herein, we systematically evaluated the availability and utility of
genetic and non-genetic factors affecting warfarin dosing in
Africa.
METHODS: Systematic comprehensive search for relevant stud-
ies was conducted in PubMed, Scopus, and Web of Science, using
appropriate search keywords. The date of last search was Novem-
ber 2017. We included observational pharmacogenetic studies per-
formed on patients from any of the African countries who were
on stable warfarin dose for sufficient time. Quality of the
included studies was assessed using “Strengthening the Reporting
of Genetic Association studies (STREGA)” guidelines.
RESULTS:We included 14 observational studies conducted on
four different populations: Ghanaian, South African, Sudanese,
and Egyptian in whom ten of the studies were conducted. Among
the commonly studied genetic variants, VKORC1 rs9923231 and
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